Session 11 – From Precision Medicine to Precision Health
Date: 24 July (Friday) 10:40 – 12:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Ruthie Davi is a Statistician and Vice President, Data Science at Acorn AI by Medidata (a Dassault Systemes Company) and has a background in pharmaceutical clinical trials with more than 20 years working as a Statistical Reviewer, Team Leader, and Deputy Division Director in the Office of Biostatistics in CDER at FDA. At Acorn AI Ruthie is part of a team creating analytical tools to improve the efficiency and rigor of clinical trials, an example of which is the Synthetic Control work. Ruthie holds a Ph.D. in Biostatistics from George Washington University
Speech title & Synopsis
In some areas of clinical development, trials are failing at unacceptable rates. Historical clinical trials have emerged as attractive options to power synthetic controls that can aid in the replacement or augmentation of control groups. This session will highlight several case studies, including Medidata’s collaborations with Friends of Cancer Research, FDA, pharma representatives and others, on how Acorn AI’s Integrated Evidence solution, Synthetic Control Arm™, can support trial design and better understanding the effectiveness of a given therapy to create better value for the patients, regulators and payors.